⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PTCT News
PTC Therapeutics, Inc.
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com
PTCT
PTC Therapeutics to Participate at Upcoming Investor Conferences
prnewswire.com
PTCT
Form 8-K
sec.gov
PTCT
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
prnewswire.com
PTCT
Phenylketonuria Market to Reach New Heights by 2034, Driven by Innovative Therapies and Rising Diagnosis Rates | DelveInsight
prnewswire.com
BMRN
PTCT
PTC Therapeutics Provides Regulatory Update on Translarna™
prnewswire.com
PTCT
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com
PTCT
PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan
prnewswire.com
PTCT
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com
PTCT
PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
prnewswire.com
PTCT